• Five take-aways from FDA’s response to drug company coalition citizen petition regarding promotion of off-label uses (Original Source)
  • Class action lawyers will do anything to keep their cases alive, even asking courts to reopen discovery so they can find replacement lead plaintiffs (Class Action Countermeasures)
  • Why POM Wonderful SCOTUS ruling doesn’t alter landscape of food labeling class actions (we agree in this post) (Class Defense)
  • SEC Commissioner addresses boards of directors’ responsibilities in preventing and responding to cyberattacks and data breaches (D&O Diary)
  • With Solicitor General’s brief in Medtronic v. Stengel, federal government changes its tune on preemption (Drug & Device Law)
  • FDA issues two more “draft guidances” on social media use to promote medical products, one of which boils down to don’t use Twitter (FDA Law Blog)
  • The Supreme Court will review a critically important matter of administrative law in its October 2014 term: when does a change in established guidance require rulemaking? (Federal Regulations Adviser)